Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term CareAuthor of the article:Last updated 17 minutes ago VANCOUVER, British Columbia & GRAPEVINE, Texas — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”) today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalantamine), donepezil, galantamine or rivastigmine. These measures provide insight into how treatment is used in real-world long-term care settings, including whether residents reach therapeutic dosing and how their broader medication regimens change over time. The analysis included both residents who had not previously received an AChEI (acetylcholinesterase inhibitor) and residents who switched from another AChEI therapy.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThis advertisement has not loaded yet, but your article continues below.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againTitration comparisons: p<0.0001. Each unadjusted between-group comparison of net concomitant medication-class burden was p<0.0001.Among residents who had not previously received an AChEI and started treatment at the initial dose, 79.1% of ZUNVEYL residents reached a therapeutic dose, compared with 37.3% receiving generic AChEIs.Approximately 80% of ZUNVEYL residents reached a therapeutic dose whether they were new to AChEI treatment or had switched from another AChEI, compared with approximately 54% of residents receiving generic AChEIs.ZUNVEYL residents discontinued about twice as many other medication classes as they added, resulting in net decreases across all eight classes evaluated. In contrast, residents receiving generic AChEIs added more than twice as many medication classes as they discontinued, with net increases across all eight classes. The classes included antidepressants, antipsychotics, anxiolytics, hypnotics, miscellaneous CNS agents, OTC gastrointestinal medications, OTC sleep aids and prescription gastrointestinal medications.CONVERGE Measure (180 Day)ZUNVEYL CohortPooled Generic AChEI CohortStarting-dose, new to AChEI treatment: reached therapeutic dose79.1% (159/201)37.3% (1,570/4,211)All-dose, new to AChEI treatment: reached therapeutic dose79.2% (160/202)53.7% (3,067/5,708)All-dose, previously treated with another AChEI: reached therapeutic dose80.7% (217/269)54.0% (279/517)Net concomitant medication-class burdenDecrease across all 8 classesIncrease across all 8 classes“We are encouraged by the CONVERGE findings across these first two measures: therapeutic dosing and changes in concomitant medication use,” said Michael McFadden, Chief Executive Officer of Alpha Cognition. “The ability to reach a therapeutic dose is an important real-world indicator of successful treatment utilization, and understanding changes in medication burden is particularly relevant in long-term care, where polypharmacy is an important consideration. These initial findings are encouraging, and we look forward to analyzing additional measures as the CONVERGE dataset continues to grow.”CONVERGE is an ongoing real-world evidence evaluation program utilizing longitudinal long-term care medication-administration data. The current analysis used PointClickCare long-term care medication-administration data through June 30, 2026. Pooled generics combined donepezil, galantamine and rivastigmine. Additional dataset updates are expected in December 2026 and March 2027 and are anticipated to expand the number of ZUNVEYL-treated residents available for future analyses. CONVERGE does not establish causality. The analyses were unadjusted for differences in resident characteristics, disease severity, treatment selection, facility practices or other potential confounders. Statistical tests reported in this release were not adjusted for multiple comparisons unless expressly stated otherwise.This advertisement has not loaded yet, but your article continues below.ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.IMPORTANT SAFETY INFORMATIONZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.: See Drug Interactions SectionCardiovascular Conditions:Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient’s weight during therapy with ZUNVEYL.Genitourinary Conditions:Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer’s disease. Patients with Alzheimer’s disease should be monitored closely for seizures while taking ZUNVEYL.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.Use with Anticholinergics:Galantamine has the potential to interfere with the activity of anticholinergic medications.Use with Cholinomimetics and Other Cholinesterase Inhibitors:A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.USE IN SPECIFIC POPULATIONSBased on animal data may cause fetal harm.In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.About Alpha Cognition Inc.Alpha Cognition Inc. is a commercial-stage biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases, including Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury.Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the interpretation and potential relevance of CONVERGE and other real-world evidence; the potential benefits, characteristics and market adoption of ZUNVEYL; and the Company’s evidence-generation, clinical-development and commercialization plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. These risks include risks related to the interpretation, completeness and generalizability of retrospective real-world data; confounding, selection bias, data quality and differences among treatment cohorts; commercial adoption, reimbursement, manufacturing and supply; regulatory oversight and pharmacovigilance; clinical-development timing and outcomes; intellectual property; liquidity and financing; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.